Angle, the Surrey-based technology investment firm, has seen its share price rocket nearly 15% on news one of its divisions has found a new way to detect prostate cancer.
Parsortix, which is 90% owned by Angle, claims its "separation technology" can capture prostate cancer cells added to blood.
The will allow for the early detection of cancer and the monitoring of patients both during and after treatment.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Angle Founder and Chief Executive, Andrew Newland, commented: "The successful capture and identification of prostate cancer cells added to blood further substantiates the potential for the Parsortix separation technology to become a market-leading product, which is simple, effective and affordable."
At 09:45, Angle shares were trading at 89.5p, up 14.5% (10.51p).
BS
-
FTSE 100 hits record highs – why is it rising and will we see more gains?Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
-
How to invest in copperIt may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
